Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125636751 | 12563675 | 1 | I | 20160711 | 20160712 | 20160715 | 20160715 | EXP | US-ASTRAZENECA-2016SE76851 | ASTRAZENECA | 224.00 | DY | F | Y | 0.00000 | 20160716 | CN | CO | CO |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125636751 | 12563675 | 1 | PS | SYNAGIS | PALIVIZUMAB | 1 | Intramuscular | 0 | 15 | MG/KG | INJECTION | /month | |||||||
| 125636751 | 12563675 | 2 | SS | SYNAGIS | PALIVIZUMAB | 1 | Intramuscular | 0 | INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125636751 | 12563675 | 1 | Bronchopulmonary dysplasia |
| 125636751 | 12563675 | 2 | Bronchopulmonary dysplasia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125636751 | 12563675 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125636751 | 12563675 | Death |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125636751 | 12563675 | 1 | 20160115 | 20160422 | 0 |